Hinxton, 10 March 2016 – The Directors of EMBL’s European Bioinformatics Institute (EMBL-EBI) are delighted to announce the appointment of Dr Andrew Leach to the post of Head of Chemistry Services.
EMBL-EBI, part of the European Molecular Biology Laboratory, is a global leader in bioinformatics – the science of storing, analysing and sharing large biological datasets – and a champion of open data in the life sciences. It provides the world’s largest collection of molecular databases, making this wealth of information freely available to researchers in industry and academia. The data resources hosted at EMBL-EBI, for example the ChEMBL database of bioactive entities, are used by millions of researchers all over the world, and provide user-friendly interfaces that enable scientists to exploit complex information to make discoveries in medicine, agriculture and the environment that benefit humankind.
Dr Leach holds BA and DPhil degrees in Chemistry from Oxford University. He joins EMBL-EBI from GSK Research and Development, where he has enjoyed a successful career since 1994, most recently as Global Head of Biomolecular Sciences. He also served as a Trustee of the Cambridge Crystallographic Data Centre from 2006-2015 and was editor of the Journal of Computer-Aided Molecular Design from 1997-2012.
“The appointment of Andrew Leach is excellent news for our chemistry services at EMBL-EBI. Dr Leach is greatly respected in the pharma world and brings with him a wealth of knowledge and experience in drug discovery and cheminformatics,” says Dr Rolf Apweiler, Director of EMBL-EBI. “As a user of EMBL-EBI resources throughout his career, Andrew brings unique insights into the pharma industry’s user requirements and an exciting vision for future exploitation of opportunities in data, analytics and computation.”
“I am honoured to have been chosen to take on the leadership of EMBL-EBI’s highly successful Chemistry services,” said Dr Leach, who will take up his new post on 1 September 2016 based at EMBL-EBI on the Wellcome Genome Campus, Hinxton, Cambridge, UK. “I know first-hand the huge value that EMBL-EBI’s resources bring to bench scientists in industry, and am looking forward to taking EMBL-EBI’s chemical biology data services to the next level.”
EMBL-EBI, part of the European Molecular Biology Laboratory, is a global leader in bioinformatics – the science of storing, analysing and sharing large biological datasets – and a champion of open data in the life sciences. It provides the world’s largest collection of molecular databases, making this wealth of information freely available to researchers in industry and academia. The data resources hosted at EMBL-EBI, for example the ChEMBL database of bioactive entities, are used by millions of researchers all over the world, and provide user-friendly interfaces that enable scientists to exploit complex information to make discoveries in medicine, agriculture and the environment that benefit humankind.
Dr Leach holds BA and DPhil degrees in Chemistry from Oxford University. He joins EMBL-EBI from GSK Research and Development, where he has enjoyed a successful career since 1994, most recently as Global Head of Biomolecular Sciences. He also served as a Trustee of the Cambridge Crystallographic Data Centre from 2006-2015 and was editor of the Journal of Computer-Aided Molecular Design from 1997-2012.
“The appointment of Andrew Leach is excellent news for our chemistry services at EMBL-EBI. Dr Leach is greatly respected in the pharma world and brings with him a wealth of knowledge and experience in drug discovery and cheminformatics,” says Dr Rolf Apweiler, Director of EMBL-EBI. “As a user of EMBL-EBI resources throughout his career, Andrew brings unique insights into the pharma industry’s user requirements and an exciting vision for future exploitation of opportunities in data, analytics and computation.”
“I am honoured to have been chosen to take on the leadership of EMBL-EBI’s highly successful Chemistry services,” said Dr Leach, who will take up his new post on 1 September 2016 based at EMBL-EBI on the Wellcome Genome Campus, Hinxton, Cambridge, UK. “I know first-hand the huge value that EMBL-EBI’s resources bring to bench scientists in industry, and am looking forward to taking EMBL-EBI’s chemical biology data services to the next level.”
